7:22 AM ET
8-K
Leadership Change
Aquestive Therapeutics Leadership Change
Aquestive Therapeutics appointed Richard J. Daly to its Board of Directors as a Class I director, effective October 14, 2026. Mr. Daly, a veteran life sciences executive with experience at AstraZeneca and Takeda, will receive an initial grant of 57,000 stock options as part of his non-employee director compensation package.
- Counterparty
- Richard J. Daly